SAbDab: The Structural Antibody Database

> Structural Summary

Therapeutic	Atezolizumab
Target	PDL1/CD274
Heavy Chain	EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSS
Light Chain	DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIK
100% seqID Fv Structure	5x8l [Fvs: FK, GL, HM, JO, SN]
99% seqID Fv Structure	5xxy [Fvs: HL]
95-98% seqID Fv Structure	None

> SAbDab Links

100% seqID Structure	5x8l [Fvs: FK, GL, HM, JO, SN]
99% seqID Structure	5xxy [Fvs: HL]

> Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Atezolizumab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

> 5xxy: H/L

Sequence identity: 99.56%

Heavy chain

Position	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	52A	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	82A	82B	82C	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	100A	101	102	103	104	105	106	107	108	109	110	111	112	113
atezolizumab	E	V	Q	L	V	E	S	G	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	A	S	G	F	T	F	S	D	S	W	I	H	W	V	R	Q	A	P	G	K	G	L	E	W	V	A	W	I	S	P	Y	G	G	S	T	Y	Y	A	D	S	V	K	G	R	F	T	I	S	A	D	T	S	K	N	T	A	Y	L	Q	M	N	S	L	R	A	E	D	T	A	V	Y	Y	C	A	R	R	H	W	P	G	G	F	D	Y	W	G	Q	G	T	L	V	T	V	S	S
5xxy	E	V	Q	L	V	E	S	G	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	A	S	G	F	T	F	S	D	S	W	I	H	W	V	R	Q	A	P	G	K	G	L	E	W	V	A	W	I	S	P	Y	G	G	S	T	Y	Y	A	D	S	V	K	G	R	F	T	I	S	A	D	T	S	K	N	T	A	Y	L	Q	M	N	S	L	R	A	E	D	T	A	V	Y	Y	C	A	R	R	H	W	P	G	G	F	D	Y	W	G	Q	G	T	L	V	T	V	S	-

Light chain

Position	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107
atezolizumab	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	R	A	S	Q	D	V	S	T	A	V	A	W	Y	Q	Q	K	P	G	K	A	P	K	L	L	I	Y	S	A	S	F	L	Y	S	G	V	P	S	R	F	S	G	S	G	S	G	T	D	F	T	L	T	I	S	S	L	Q	P	E	D	F	A	T	Y	Y	C	Q	Q	Y	L	Y	H	P	A	T	F	G	Q	G	T	K	V	E	I	K
5xxy	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	R	A	S	Q	D	V	S	T	A	V	A	W	Y	Q	Q	K	P	G	K	A	P	K	L	L	I	Y	S	A	S	F	L	Y	S	G	V	P	S	R	F	S	G	S	G	S	G	T	D	F	T	L	T	I	S	S	L	Q	P	E	D	F	A	T	Y	Y	C	Q	Q	Y	L	Y	H	P	A	T	F	G	Q	G	T	K	V	E	I	K

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder2
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

> Metadata

Format	Whole mAb
Isotype	G1
Highest Clinical Trial (Aug '24)	Approved
Estimated Status (Aug '24)	Active
Recorded Developmental Technology	Human Phage Display
INN Year Proposed	2014
INN Year Recommended	2015
Companies Involved	Amgen, ARCAGY/GINECO Group, BioLineRx, Chugai Pharmaceutical, Clovis Oncology, Dana-Farber Cancer Institute, Duke University, European Organisation for Research and Treatment of Cancer, Exelixis, Fondazione Michelangelo, GEICO (Spanish Ovarian Cancer Research Group), Genentech, GERCOR, Gradalis, H. Lee Moffitt Cancer Center and Research Institute, Immune Design, Incyte Corporation, Johns Hopkins University, Kaiser Permanente, M. D. Anderson Cancer Center, Memorial Sloan-Kettering Cancer Center, National Cancer Center (Korea), National Cancer Institute (USA), Netherlands Cancer Institute, Roche, Sanofi, Seattle Genetics, University Hospital Southampton NHS Foundation Trust, University Medical Center Groningen, University of California, University of California at San Francisco, University of Oklahoma, Yale University
Conditions Approved	Non-small cell lung cancer, Urogenital cancer, Breast cancer, Small cell lung cancer
Conditions Active	Bladder cancer, Cervical cancer, Colorectal cancer, Fallopian tube cancer, Head and neck cancer, Liver cancer, Malignant melanoma, Ovarian cancer, Peritoneal cancer, Prostate cancer, Renal cell carcinoma, Anal cancer, Brain metastases, Chronic lymphocytic leukaemia, Cutaneous T-cell lymphoma, Diffuse large B cell lymphoma, Endometrial cancer, Gastric cancer, Gynaecological cancer, Mantle-cell lymphoma, Marginal zone B-cell lymphoma, Oesophageal cancer, Soft tissue sarcoma, Solid tumours, Thyroid cancer, Waldenstrom's macroglobulinaemia, Acute myeloid leukaemia, Follicular lymphoma, Glioblastoma, Pancreatic cancer, Haematological malignancies, Multiple myeloma, Non-Hodgkin's lymphoma
Conditions Discontinued	Hodgkin's disease, Myelodysplastic syndromes
Notes

Thera-SAbDab

ATEZOLIZUMAB